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Abstract
Epigenetic mechanisms such as microRNA and histone modification are crucially responsible for dysregulated gene
expression in heart failure. In contrast, the role of DNA methylation, another well-characterized epigenetic mark, is
unknown. In order to examine whether human cardiomyopathy of different etiologies are connected by a unifying pattern
of DNA methylation pattern, we undertook profiling with ischaemic and idiopathic end-stage cardiomyopathic left
ventricular (LV) explants from patients who had undergone cardiac transplantation compared to normal control. We
performed a preliminary analysis using methylated-DNA immunoprecipitation-chip (MeDIP-chip), validated differential
methylation loci by bisulfite-(BS) PCR and high throughput sequencing, and identified 3 angiogenesis-related genetic loci
that were differentially methylated. Using quantitative RT-PCR, we found that the expression of these genes differed
significantly between CM hearts and normal control (p,0.01). Moreover, for each individual LV tissue, differential
methylation showed a predicted correlation to differential expression of the corresponding gene. Thus, differential DNA
methylation exists in human cardiomyopathy. In this series of heterogenous cardiomyopathic LV explants, differential DNA
methylation was found in at least 3 angiogenesis-related genes. While in other systems, changes in DNA methylation at
specific genomic loci usually precede changes in the expression of corresponding genes, our current findings in
cardiomyopathy merit further investigation to determine whether DNA methylation changes play a causative role in the
progression of heart failure.
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Introduction
The pathogenesis of heart failure involves molecular mecha-
nisms which are becoming better understood [1,2] and studies in
both experimental models and humans demonstrate the important
relevance of dysregulated gene expression [1,3]. Furthermore,
transcriptomic analyses of human dilated cardiomyopathy show a
consistent and distinct pattern of gene expression [4], and
dysregulated expression of both coding and non-coding genes
directly affects heart failure development and progression [3,5].
Higher order mechanisms such as microRNA [5,6] and histone
modifications [7,8] can alter gene expression control in cardio-
vascular disease, without involving any change in the underlying
DNA sequence. The direct covalent modification of DNA cytosine
nucleotides by methylation is another well-recognized epigenetic
mechanism but its role in cardiovascular disease is unknown. DNA
cytosine-methylation alters accessibility for transcription factor
complexes at a local level and, like histone modifications, affects
chromatin structure at regional and genome-wide levels. A well-
characterised functional effect of DNA methylation is thus control
of gene expression [9]. In this respect, hypomethylation of the 59
promoter end of a gene correlates with increased expression of the
gene [9], whereas hypermethylation within the body of a gene, is
linked to increased gene expression [10,11]. Although a direct
molecular mechanism to explain these observations is still lacking,
basic mechanisms by which DNA methyl-transferases and putative
DNA de-methylase complexes function have recently been
uncovered [12–14]. Complementary to this, one of the most
important findings in the field of epigenetics in recent times is the
discovery of DNA methylation variation between individuals at a
genome-wide level [15]. Evidence indicates that this variation may
be in part inherited [15] and in part, acquired [16,17]. At least
through its control of gene expression, DNA methylation variation
may account for complex disease susceptibility or progression
[15,18].
For instance, Fraga et al [19] found that although monozygotic
twins share a common genotype and DNA methylation was
indistinguishable in younger twins, older twins exhibited remark-
able methylation differences that correlated with a pattern of
differential gene expression. Similarly, consistent with the notion
of drifts in DNA methylation with increasing age, acquired
variation in DNA methylation has been attributed to causes such
as environmental, hormonal and stochastic events [16,17,20].
Differential DNA methylation, either through its influence on gene
expression or other yet unknown mechanisms, could therefore
explain differences in disease susceptibility or phenotypic discor-
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DNA sequences. In the wider population, differential DNA
methylation may similarly contribute to the diversity of pheno-
types, pathogenesis and progression of complex diseases. Apart
from the strong association already identified between differential
DNA methylation and cancer [21], there are now on-going efforts
to investigate the link between DNA methylation variation and
other complex diseases such as schizophrenia [22], diabetes [23]
and inflammatory bowel disease [24].
Here, we tested the hypothesis that global DNA methylation
profiles in human cardiac tissue differ between cardiomyopathy
and normal control, and aimed to identify a subset of genomic loci
whose differential methylation is correlated to differential
expression of their corresponding genes.
Results
Differentially Methylated DNA Regions in Dilated
Cardiomyopathy (CM-DMRs)
As a proof of concept that DNA methylation in a subset of
genomic loci may connect end-stage cardiomyopathy with
different etiologies, we set out initially to profile a series of
heterogenous cardiomyopathic left ventricles and a single normal
control (diseased: samples I, II, III; control: sample A; Table 1)
using MeDIP-chip (Method summarised in Figure S1). We used
the Nimblegen ‘‘CpG island and promoter’’ microarray chip
(Roche Nimblegen, WI) which covers all annotated Human
Refseq gene promoters (24,659) and CpG islands (28,226) as
annotated on the UCSC genome browser.
Based on a DMR (differentially methylated region) T-
statistic.+3.0 and ,23.0, candidate regions (CM-DMRs) were
identified using the validated algorithm-Bayesian tool that had
been developed specifically for handling MeDIP data (BAT-
MAN)[25–26] (Figures S1 and S2). Of the target CM-DMRs
meeting these criteria, three candidates were identified by gene
ontology analysis and GENECARDS to relate to angiogenesis
(AMOTL2, ARHGAP24 and PECAM1, Figure 1 and Figure S4).
Next, we undertook bisulfite-(BS) PCR and massive parallel
amplicon sequencing for these CM-DMRs using a second and
larger set of LV samples (diseased: III, IV, V, VI; and controls: B,
C, D, E; Table 1). Bisulfite treatment of gDNA converts
unmethylated-cytosine nucleotides to uracil but leaves methylat-
ed-cytosine residues unaffected. This difference is then detected as
a C/T nucleotide polymorphism at each CpG site by subsequent
PCR and sequencing, providing the gold-standard high-resolution
information about the methylation status of a DNA region.
Amplicon sequences were matched to the reference Human
Genome and DNA methylation (%) for each locus was determined
(Figure 1).
Differential Expression of Genes Related to CM-DMR
Although epigenetics may direct complex effects including
changes in higher-order chromatin structure, DNA methylation
differences are at least currently understood to control gene
expression. At the local DNA level, hypomethylation in the 59 or
promoter region of a gene is associated with increased transcrip-
tion; whereas hypermethylation of the body of a gene is associated
with its active transcription [10,11]. We therefore set out to
determine expression of the target genes that we have identified.
Before quantifying target gene expression, we ascertained that
our LV samples had at least 10-fold upregulated levels of NPPA
mRNA compared to controls (Figure S3, p=0.008). NPPA is
upregulated in cardiomyopathy and represents the fetal gene
program re-induction that is expected for myocardial disease [1].
Differential DNA methylation at the NPPA gene CpG island and
promoter locus was however absent on MeDIP-chip (data not
Table 1. Details of patient LV samples.
LV sample Code Age Details Medications
Control A 41 Asian -
B 47 RTA -
C 50 RTA -
D 41 RTA -
E 52 RTA -
F 50 Hypoxic brain damage secondary to drowning -
End-stage cardiomyopathy I 49 LV non-compaction, no history of coronary
artery disease
Bumetanine, Amiodarone, Enalapril
II 53 Idiopathic, no history of CAD Aspirin. Bisoprolol, Frusemide, Spironolactone
III 64 Ischaemic, diabetic Clopidogrel, Ramipril, Digoxin, Spironolactone,
Bumetanide, Gliclazide, Simvastatin
IV 42 Idiopathic, no history of CAD Perindopril, Carvedilol, Warfarin
V 64 Idiopathic, no history of CAD Frusemide, Spironolactone, Lisinopril, Amiodarone,
Atorvastatin, Warfarin
VI 61 Ischaemic Clopidogrel, Perindopril, Nicorandil, Bisoprolol, Imdur,
Spironolactone, Frusemide, Digoxin, Simvastatin
VII 60 Ischaemic, diabetic Aspirin, Clopidogrel, Ramipril, Bisoprolol, Frusemide,
Spironolactone, Frusemide, Insulin
VIII 58 Ischaemic Aspirin, Ramipril, Carvedilol, Frusemide, Digoxin,
Atorvastatin
RTA: road traffic accident; all LV samples were from Caucasian males (except A: Asian male).
CAD: coronary artery disease.
doi:10.1371/journal.pone.0008564.t001
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controlled by DNA methylation in this context or differential
NPPA gene expression may correlate to differential methylation at
a non-CpG island locus that was not present on the Nimblegen
chip.
In contrast, qPCR for transcripts of the 3 genes that were
associated with the 3 CM-DMRs that we had identified, showed
statistically significant differential expression between control LV
and CM LV (Figure 2; p=0.004 for AMOLT2, p,0.001 for
ARHGAP24, p=0.006 for PECAM1). Consistent with the predicted
effect of hypermethylation in the 59 regulatory region of genes,
hypermethylation in the 59 region of PECAM1 in dilated hearts
(DMR11, Figure 1C) correlated with decreased expression of
PECAM1 (Figure 2C). Similarly consistent with the predicted effect
of gene body methylation, hypomethylation within the gene body
of AMOTL2 (DMR24, Figure 1A) correlated with reduced
expression of AMOTL2 (Figure 2A); and hypermethylation within
the gene body of ARHGAP24 (DMR36, Figure 1B) correlated with
increased expression of ARHGAP24 (Figure 2B).
We further analysed the correlation between gene expression
and differential methylation in each individual LV tissue directly
and independently of disease, and found as predicted, that 59
Figure 1. Differential DNA methylation profile for 3 candidate CM-DMR. (A) DMR24, (B) DMR36 and (C) DMR11. DNA methylation (%) was
determined for a set of 8 LV samples (4 controls: B–E, 4 diseased (CM): IV–VII) by BS-PCR-sequencing as detailed in methods. Lower panel, DMR24 and
DMR36 lie within the body of the genes: AMOTL2 and ARHGAP24; whereas DMR11 lies in the 59 regulatory region of PECAM1.
doi:10.1371/journal.pone.0008564.g001
Figure 2. Differential DNA methylation for 3 CM-DMR correlates with differential gene expression. (A–C) Gene expression profiles for
the gene corresponding to each DMR: AMOTL2, ARHGAP24, and PECAM1. Quantitative PCR was performed in a set of 11 LV samples (4 controls: C–F,
7 CM: II–VIII). QPCR experiments were performed in triplicate for each sample. ** p,0.05. (D–F) Correlation between gene expression and DNA
methylation using Spearmans rank order correlation coefficient.
doi:10.1371/journal.pone.0008564.g002
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(DMR11 in Figure 2F). Similarly for DMR24 and DMR36, a
positive correlation existed between gene body methylation and
gene expression (Figure 2D and E). Importantly, although
differential gene expression patterns were opposite for AMOTL2
and ARHGAP24 in dilated hearts (decreased and increased
expression respectively), the correlation between methylation and
gene expression was positive in both. Moreover, individual LV
samples with the highest or lowest expression of each of these
genes mapped to the predicted methylation state in their
correlation between methylation and expression independently
of disease state.
Discussion
In eukaryotes, DNA methylation occurs by the addition of a
methyl group to the carbon 59 position of the nucleotide cytosine
ring, and cytosine methylation in mammals, is found most
commonly in the context of the sequence 59-CG-39, which is also
referred to as a CpG dinucleotide. In the mammalian genome, an
estimated 70% of all CpGs are methylated [27]. Unmethylated
CpG on the other hand are largely grouped in clusters called
‘‘CpG islands’’ in the 59 regulatory region of many genes. The
frequency of CpG dinucleotides in ‘‘CpG islands’’ is higher than is
found in other DNA regions. Notably, differential methylation of
CpG islands is part of the epigenetic variation found in humans
[18,27].
Consistent withpreviousobservationscorrelating geneexpression
with DNA methylation [9–11], we have found that hypermethyla-
tion within the 59 region of the PECAM1 gene correlated with its
reduced expression in different cardiac samples. Hypermethylation
withinthebodyoftheARHGAP24 gene correlated with itsincreased
expression; and hypomethylation within the body of the AMOTL2
gene correlated with its decreased expression. Although our study
was not designed to address the question of causality, current
evidence suggests that locus-specific DNA methylation either
permissively or necessarily controls gene-specific expression
[16,17,21,27]. This may occur by the binding of methylated DNA
binding domain (MBD) proteins and polycomb group proteins
which displaces the transcription machinery and thereby maintain-
ing epigenetic silencing of transcriptional activity [9]. The
hypermethylation mark may in some cases, be laid down
subsequent to transcriptional down-regulation of a gene [28], but
experiments using the DNA methyl-transferase inhibitor (59-
deoxyazacytidine) show that de-methylation of a specific gene
promoter can re-establish gene expression [21,29]. Similarly the
interaction between histone modification and DNA methylation in
regulating gene expression is currently unclear, and may indeed be
locus specific. At least in some cases, histone deacetylase inhibitors
suchasTrichostatinA isalsorequired with de-methylating agents in
order to restore gene expression in an otherwise densely methylated
gene locus [30]. The interaction between histone de-acetylation and
DNA methylation in myocardial disease will be particularly
important to understand since the critical role of histone
deacetylases (HDAC) in cardiac hypertrophy and heart failure has
already been established [8,31].
This is the first demonstration that differential DNA methyla-
tion exists between human end-stage cardiomyopathic hearts and
normal controls. The utility of the MeDIP-chip dataset may be
limited because only a single control heart was used, but we have
also used a second series of hearts and verified using the second
methodology of bisulphite sequencing, that differential methyla-
tion exists in heart failure. Moreover despite the heterogeneity of
our samples, we have found that for at least 3 genomic loci,
differential methylation corresponds to differential gene expres-
sion. This was anticipated since several disease processes and
molecular pathways such as apoptosis, dyregulated calcium
signalling, decompensated contractility, G-coupled protein recep-
tor down-regulation, and maladaptive angiogenesis also connect
cardiomyopathy of disparate etiologies [2]. Dysregulated gene
expression and differential DNA methylation of angiogenic factors
may indeed connect heart failure with different etiologies, in the
same manner that raised levels of NPPA and the re-induction of a
fetal gene programme marks heart failure irregardless of its
inciting cause [2]. As with cDNA microarray experiments utilizing
whole heart tissue with mixed cell populations, our findings may
also reflect a change in the predominance of a particular cell type
in each tissue sample. We have however not detected any
expression pattern change in gene families that are characteristi-
cally specific to non-myocyte cell types such as fibroblasts (data not
shown).
At a broad genomic level, 3-dimensional intra-chromosomal and
inter-chromosomal DNA-DNA interactions may partition the
genome into active and inactive domains [32]. These interactions
characteristically involve DNA regulatory elements. Protein com-
plexes comprising of DNA-binding proteins bound to these
regulatory elements may hold together DNA conformations to
form chromatin centres of active transcription or transcriptional
factories. By altering access to DNA-binding proteins, different
DNA methylation states of these DNA regulatory elements in
disease versus control may therefore be responsible for important
changes in 3-D conformations and hene, gene expression [33].
Although in this study, we have examined the effect of DNA
methylation on local proximal gene expression, instead of a linear
series of genes and promoters, the 3-D model of transcriptional
regulatory networks [32] suggests that altered DNA methylation
may influence the expression of genes in sites that are distal or
distant [33]. Nevertheless for the control of proximal gene
expression, others have previously reported that a 6% methylation
difference within the RASSF1 gene comparing between methylation
profiles of the cerebellum and cerebrum corresponded with a 2-fold
differenceinRASSF1gene expressioninthese2 different parts ofthe
brain [22]. More recently Barres et al showed that 2–5%
methylation difference in the PGC1A promoter related to a 3.5 fold
difference in PGC1a gene expression in the vastus lateralis muscle of
patients with type IIdiabetes[23]. Inbreast cancer,8%methylation
difference was associated with a 1.5 to 3.5 fold expression difference
of the ATM gene [34]; and comparing between children conceived
in vitro or in vivo, 7% and 9.7% methylation difference in the COPG2
and CEBPA genes related to 2.05 and 1.77 fold changes in gene
expressionrespectively[35].UsingtheBS-PCR-sequencingstrategy
we have found here that differential methylation between control
and CM ranged up to 32% (Figure S1 and data not shown). More
importantly, we have demonstrated the biological significance for
this range of differential methylation in 3 DMRs. In the case of
DMR24/AMOTL2, 2–3% differential methylation between dis-
eased hearts and controls correlated with a 2.5-fold decrease in
AMOTL2 gene expression. For DMR36/ARHGAP24, a 3–5%
difference in methylation corresponded to a 2.5-fold increase in
gene expression.
Functionally, AMOTL2 belongs to the angiomotin family which
mediates inhibition of endothelial cell migration and tube
formation by binding to angiostatin [36]. ARHGAP genes encode
RhoGAP family proteins, and using subtraction-hybridization in
endothelial cells undergoing capillary-tube formation, ARHGAP24
(also known as p73RhoGAP) was also found to regulate capillary-
tube formation [37]. ARHGAP24 expression was up-regulated in
an angiogenic milieu but unchanged under non-angiogenic
DNA Methylation, Heart Failure
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its expression in angiogenesis have also long been investigated
[38,39]. Our current findings implicating the differential expres-
sion of these 3 genes in end-stage heart failure may reflect adaptive
or maladaptive angiogenic processes in disease pathogenesis, and
will require further direct investigation. Even so, a transcriptomic
analysis that was performed recently using endomyocardial
biopsies from patients with new onset heart failure revealed that
disease prognosis may be predicted based on the expression profile
of a series of genes included genes of angiogenic factors, one of
which was ARHGAP26 [4]. Moreover, the important role of
angiogenesis has been demonstrated before, both in human
ischaemic heart disease [40] and experimental models of non-
ischaemic related heart failure [41].
Our results show that differential DNA methylation occurs in
human end-stage cardiomyopathy. Gene expression is dysregulat-
ed in heart failure and a subset of this connecting end-stage disease
with different etiologies may be explained by differential DNA
methylation together with other epigenetic mechanisms such as
histone de-acetylation. As these epigenetic mechanisms may be
altered by the environment and diet, differential DNA methylation
may be responsible for integrating environmental/dietary signals
and inherited traits to influence heart failure pathogenesis and
progression. Larger studies will be needed to identify other
differentially methylated genomic loci that bear a statistically
significant association to heart failure. Moreover recent evidence
suggests that future analysis should also include DNA regions
outside of CpG islands because at least in human colon cancer,
significant methylation variation was found in sequences .2k b
away from promoters and CpG islands (termed ‘‘CpG island
shores’’) [42]. Unravelling these additional complex layere of gene
expression control will improve therapeutic options and alter
patient management for this complex disease.
Materials and Methods
Ethics Statement
Human myocardium was collected by a protocol approved by
the Papworth (Cambridge) Hospital Tissue Bank review board and
the Cambridgeshire Research Ethics Committee (UK). Written
consent was obtained from every individual according to the
Papworth Tissue Bank protocol.
Human Left Ventricular Myocardium
Left ventricular (LV) tissue was obtained from male patients
undergoing cardiac transplant for end-stage heart failure. Normal
non-donor suitable human LV tissue was from healthy male
individuals involved in road traffic accidents. At the time of
transplantation or donor harvest, whole hearts were removed after
preservation and transported in cold cardioplegic solution
(cardioplegia formula and Hartmann’s solution) similar to the
procedure described before at Imperial College, London [43].
Following analysis by a cardiovascular pathologist (M.G.), left
ventricular segments were cut and stored immediately in
RNAlater (Ambion, Austin, Tx). Individual patient details are
listed in Table 1. Integrity of genomic DNA (gDNA) and RNA
isolated from each tissue was verified by Nanodrop (Thermo
Scientific, Wilmington, DE), QIAxcel system (Qiagen, Crawley,
West Sussex, UK) (for DNA) and 2100 Bioanalyzer (Agilent
Technologies, Stockport, Cheshire, UK) (for RNA).
Genomic DNA Isolation
gDNA was isolated from LV samples using Genomic DNA
G100 Tips (Qiagen, Crawley, UK). Samples were homogenised
using a hand-held homogenizer, treated with 200 mg/ml RNase A
(Qiagen) for 15 min at room temperature and thereafter digested




According to protocols previously described (26–28), at least
25 mg of gDNA sample was diluted in TE buffer (10 mM Tris-
HCl, pH 7.5, 1 mM EDTA) and sheared to between 100–800 bp
fragments using Bioruptor (Diagenode, Belgium). 4 mgo fe a c h
sample was saved as INPUT and the rest heated to 95uCf o r
10 min and immediately placed on ice. Immunoprecipitated was
performed using 2.5 mgo fa-59methyl-cytosine antibody per mg
of sheared gDNA in IP buffer (20 mM Na-Phosphate, pH 7.0,
1 M NaCl, 2% Triton-X100). Samples were rotated overnight at
4uCa n d1 0ml of 50% Protein-A Agarose slurry (pre-washed in
0.1% BSA-PBS and equilibrated in IP buffer) was subsequently
added per mg of DNA. Samples were rotated for further 2.5 hr
and washed 3 times with IP buffer before elution using 250 ml
lysis buffer (1 M Tris-HCl, pH 8.0, 0.5 M EDTA, 10% SDS,
280 mg/ml Proteinase K) and incubation for 2 hr at 55uC.
MeDIP was purified and precipitated using phenol and
chloroform:isoamyl alcohol. The extent of methylated DNA
enrichment in our MeDIP samples was verified by qPCR for the
normally methylated target region of OXT (Figure S1B and
Figure S4). We also verified the expected depletion of the
unmethylated target region of UBE2B.
Four-mg of INPUT and MeDIP for each sample were labelled
with Cy3 and Cy5, respectively and co-hybridised to the
Nimblegen ‘‘CpG island and promoter’’ microarray chip (Nim-
blegen, WI). This Nimblegen array chip comprises of 385,000
isothermal probes of between 50–75 mer length with a median
probe spacing of 101 bp, and is based on the HG18 human
genome assembly. These probes cover all reported Human Refseq
gene promoters (24,659) that ranged from 2800 bp to +200 bp
relative to transcription start sites (TSS) and all reported CpG
islands (28,226) annotated on the UCSC genome browser.
Bisulfite Treatment of gDNA, PCR and Massive Parallel
Amplicon Sequencing
Bisulfite (BS) conversion of gDNA was performed using the EZ
DNA Methylation-Gold kit (Zymo Research, Orange, CA)
according to manufacturer’s protocol. PCR was performed using
BS-treated gDNA samples as template, and BS-specific primers
that were designed at a minimum length of 20 bp against selected
DMRs using the MethPrimer program. (http://www.urogene.
org/methprimer/index1.html). Composite primers were designed
by incorporating 19 bp Roche FLX Primer-A and Primer-B
specific sequences to the 59-ends of Forward and Reverse primers
respectively.
Primers were tested to confirm the amplification of BS-treated
gDNA only and individual PCR products were run on 2% agarose
gels to verify product size (data not shown). Concentration of PCR
amplicons was determined using the QIAxcel system and
amplicons from each LV sample were pooled at equimolar
concentrations and sequenced on individual lanes in a Next
Generation 454 FLX sequencing machine (Roche). We obtained
between a 4.4–7.3 million bp reads per sample per lane of FLX
sequencing which corresponds to an average number of 24,000
reads of 250 bp average product size per lane. This in turn
corresponded to an average depth of about 1,100 reads per
individual PCR product.
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products were aligned to the Human Reference Genome, and
the extent of methylation (DNA methylation%) was determined by
comparing the total number of Cs (methylated) to Ts (unmethy-
lated) for each CpG site in a single DMR.
RNA Extraction, cDNA Synthesis and Expression
Quantitative PCR
At least 30 mg of frozen LV sample was thawed in 1 ml of TRI-
reagent (Sigma-Aldrich, St Louis, MO) and homogenised for 3
times 20 sec bursts, using the Lysing Matrix (QBiogene, Cam-
bridge, UK) in a FastPrep machine (FP120, QBiogene). Thereafter,
beads were centrifuged at 3000 rpm for 3 min, supernatant
transferred to a clean Eppendorf and RNA extraction was
performed according to manufacturer’s protocol. Twenty-mlo f
cDNA was synthesised from 1 mg of Total RNA, using a mixture of
both oligo-dT and random hexamers and the ‘‘Superscript-III first
strand cDNA synthesis kit’’ (Invitrogen, Paisley, UK). Integrity of
RNA for all samples was checked using the 2100 Bioanalyzer
(Agilent Technologies). Quantitative real-time PCR for house
keeping genes was initially performed using 4 ml of 1:20 pre-diluted
cDNA in a 20 ml reaction and Taqman Gene Expression Assays
specific for 18S, GAPDH, RPLPO and TBP. Using geNorm
(http://medgen.ugent.be/,jvdesomp/genorm/#PrimerDesign) we
determined that of these housekeeping genes, RPLPO was most
stable for both control and diseased samples. Quantitative PCR
performed for target genes using validated Taqman Gene Expression
Assay primers (Applied Biosystems, Foster City, CA) was therefore
normalised against RPLPO. Quantitative PCR for both target genes
and RPLPO were performed at least in triplicate on the same diluted
cDNA samples.
Statistical Analysis
Analysis for MeDIP-chip was performed using the BATMAN
algorithm as previously described (27). Analysis for quantitative
PCR was performed using the non-parametric Mann-Whitney t-
test and two-tailed p values were used to determine statistical
significance. Analysis for the association between DNA methyla-
tion and gene expression was performed using Spearmans rank
order correlation coefficient.
Supporting Information
Figure S1 Methodology (A) Work flow for MeDIP-chip and BS-
PCR-sequencing using different sets of LV samples. (B) Enrich-
ment for methylated gene, OXT, and non-enrichment of
unmethylated gene, UBE2B, demonstrated by qPCR validates
the effectiveness of MeDIP.
Found at: doi:10.1371/journal.pone.0008564.s001 (1.28 MB TIF)
Figure S2 Global differential DNA methylation in end-stage
dilated cardiomyopathy. BATMAN analysis of MeDIP-chip for
one control LV vs. average of 3 LV from end-stage cardiomyop-
athy hearts (CM). Heatmap represents BATMAN DMR T-
statistic score.
Found at: doi:10.1371/journal.pone.0008564.s002 (4.91 MB TIF)
Figure S3 Quantitative PCR for NPPA showing .10-fold
upregulation in CM samples compared to control.
Found at: doi:10.1371/journal.pone.0008564.s003 (0.20 MB TIF)
Figure S4 Examples for 3 CM-DMRs that were identified by
MeDIP-chip in relation to an integrated resource of tissue-DMRs
in other normal somatic and germ-line tissues (ref. 28).
Found at: doi:10.1371/journal.pone.0008564.s004 (4.95 MB TIF)
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